ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 167,50
-0,26%
Dow Jones
39 907,01
0,09%
DAX
18 704,42
-0,11%
Brent Oil
83,395
0,23%
Bitcoin
67 169,23
2,96%
Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Novan Inc (NOVN)

  7. Novan Inc (NOVN) Actualités

NOVN

Novan (NOVN)

Novan Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NOVN
DateHeureSourceTitreSymboleSociété
02/05/202406h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NOVNNovan Inc
01/05/202417h49Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:NOVNNovan Inc
25/03/202413h54Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NOVNNovan Inc
05/01/202415h23GlobeNewswire Inc.Novartis expands production of Pluvicto™ with addition of its largest and most advanced radioligand therapy manufacturing facility in IndianapolisNASDAQ:NOVNNovan Inc
11/12/202301h30GlobeNewswire Inc.Novartis presents new 48-week results from Phase III APPLY-PNH trial showing sustained efficacy and long-term safety of Fabhalta® (iptacopan) in adults with paroxysmal nocturnal hemoglobinuria (PNH)NASDAQ:NOVNNovan Inc
08/12/202315h15GlobeNewswire Inc.Latest Novartis Kisqali® NATALEE analysis reinforces 25% reduction in risk of recurrence across broad population of patients with early breast cancer; supports regulatory submissionsNASDAQ:NOVNNovan Inc
06/12/202301h16GlobeNewswire Inc.Novartis receives FDA approval for Fabhalta® (iptacopan), offering superior hemoglobin improvement in the absence of transfusions as the first oral monotherapy for adults with PNHNASDAQ:NOVNNovan Inc
20/11/202307h15GlobeNewswire Inc.Novartis showcases significant data updates from Kisqali®, iptacopan and Scemblix® at SABCS and ASHNASDAQ:NOVNNovan Inc
17/07/202314h45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:NOVNNovan Inc
28/06/202300h30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NOVNNovan Inc
16/06/202323h02Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NOVNNovan Inc
05/06/202315h00GlobeNewswire Inc.Novan to Provide Corporate Update at its 2023 Annual Meeting of StockholdersNASDAQ:NOVNNovan Inc
31/05/202322h05GlobeNewswire Inc.Novan Focuses Strategic Direction and Announces RestructuringNASDAQ:NOVNNovan Inc
15/05/202312h56Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:NOVNNovan Inc
15/05/202312h45GlobeNewswire Inc.Novan Reports First Quarter 2023 Financial Results and Provides Corporate UpdateNASDAQ:NOVNNovan Inc
08/05/202315h05GlobeNewswire Inc.Novan to Report First Quarter 2023 Financial Results on May 15, 2023NASDAQ:NOVNNovan Inc
27/04/202315h10GlobeNewswire Inc.Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹NASDAQ:NOVNNovan Inc
27/04/202315h00Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:NOVNNovan Inc
20/04/202315h00GlobeNewswire Inc.Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhDNASDAQ:NOVNNovan Inc
30/03/202312h30GlobeNewswire Inc.Novan Reports Full Year 2022 Financial Results and Provides Corporate UpdateNASDAQ:NOVNNovan Inc
23/03/202314h00GlobeNewswire Inc.Novan to Report Full Year 2022 Financial Results on March 30, 2023NASDAQ:NOVNNovan Inc
20/03/202314h38Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:NOVNNovan Inc
20/03/202300h00GlobeNewswire Inc.Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing; 100% achievement of all assessed milestones in children treated prior to SMA symptom onsetNASDAQ:NOVNNovan Inc
16/03/202323h47GlobeNewswire Inc.Novartis Tafinlar + Mekinist approved by FDA for pediatric patients with BRAF V600E low-grade glioma, the most common pediatric brain cancerNASDAQ:NOVNNovan Inc
16/03/202321h15GlobeNewswire Inc.Novan Announces Closing of $6.0 Million Registered Direct OfferingNASDAQ:NOVNNovan Inc
14/03/202313h30GlobeNewswire Inc.Novan to Present at the Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:NOVNNovan Inc
14/03/202313h00GlobeNewswire Inc.Novan Announces $6.0 Million Registered Direct OfferingNASDAQ:NOVNNovan Inc
08/03/202315h00GlobeNewswire Inc.Novan Moves Forward with Unified Corporate BrandingNASDAQ:NOVNNovan Inc
07/03/202314h00GlobeNewswire Inc.FDA Accepts Novan’s NDA for Berdazimer Gel, 10.3% for the Treatment of Molluscum Contagiosum with a PDUFA Goal Date of January 5, 2024NASDAQ:NOVNNovan Inc
18/01/202314h05GlobeNewswire Inc.Novan to Present at the Virtual Investor 2023 Companies to Watch EventNASDAQ:NOVNNovan Inc
 Showing the most relevant articles for your search:NASDAQ:NOVN

Dernières Valeurs Consultées

NASDAQ
ALLI
ASX
YTMLL1
Theta Asset Management L...
TSXV
NDR
New Dimension Resources
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés